ÆÄºê¸®º´ Ä¡·á ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Fabry Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
»óǰÄÚµå : 1699415
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,676,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,329,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,495,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÆÐºê¸®º´ Ä¡·á ½ÃÀåÀº 2024³â 23¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2034³â ¿¬Æò±Õ 8.2% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÆÄºê¸®º´¿¡ ´ëÇÑ ¸Å¿ì È¿°úÀûÀ̰í Ç¥ÀûÈ­µÈ ƯÀÌÀû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¼¼°è ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÆÄºê¸®º´Àº GLA À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇØ ¹ß»ýÇÏ´Â Èñ±Í À¯Àü¼º ÁúȯÀ¸·Î ´Ù¾çÇÑ Àå±â¿¡ À¯ÇØÇÑ Áö¹æ ¹°ÁúÀÌ ÃàÀûµÇ¾î ½ÅÀå, ½ÉÀå, ½Å°æ°è¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÏ´Â Èñ±Í À¯ÀüÁúȯÀÔ´Ï´Ù. ÆÄºê¸®º´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·áÁø°ú Á¦¾à»çµéÀº Áõ»ó°ú ±Ùº»ÀûÀÎ ¿øÀÎÀ» ¸ðµÎ ÇØ°áÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸¿Í ÀÓ»óÀû ¹ßÀüÀ¸·Î »õ·Î¿î Ä¡·á ¿É¼ÇÀÌ »ý°Ü³ª¸é¼­ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ýÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. ¹Î°ü ¾ç ºÎ¹®ÀÇ ÀÚ±Ý Áö¿ø Áõ°¡¿Í ¹ÙÀÌ¿À Á¦¾à»ç°£ÀÇ Á¦ÈÞ·Î ÀÌ ½ÃÀå¿¡¼­ÀÇ ±â¼ú Çõ½ÅÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î Ä¡·áÁ¦ÀÇ ÆÐ½ºÆ®Æ®·¢ ÁöÁ¤¿¡ µû¸¥ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀ¸·Î ÀǾàǰ ½ÂÀÎÀÌ ´õ¿í »¡¶óÁö°í ÀÖÀ¸¸ç, ÀÌ´Â ¾÷°è Âü¿©Àڵ鿡°Ô À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ÁøÈ­Çϰí ÀÖÀ¸¸ç, ±â¾÷µéÀº º¸´Ù È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î Ä¡·á¹ýÀ» ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

Fabry Disease Treatment Market-IMG1

½ÃÀåÀº ¿©·¯ Ä¡·á¹ýÀ¸·Î ºÐ·ùµÇÁö¸¸, È¿¼Ò´ëü¿ä¹ý(ERT)ÀÌ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, 2024³â ERT ½ÃÀå ±Ô¸ð´Â 17¾ï ´Þ·¯·Î, ÆÄºê¸®º´ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î¼­ÀÇ ¿ªÇÒÀÌ È®¸³µÇ¾î Àֱ⠶§¹®¿¡ °è¼Ó ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº °áÇÌµÈ È¿¼ÒÀÎ ¾ËÆÄ-°¥¶ôÅä½Ã´Ù¾ÆÁ¦ A¸¦ º¸ÃæÇÔÀ¸·Î½á È¿°ú¸¦ ¹ßÈÖÇϸç, ÀÌ ÁúȯÀÇ °ü¸®¿Í ÁøÇ༺ Àå±â ¼Õ»óÀ» ¿¹¹æÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÆÄºê¸®º´ÀÇ À¯º´·ü Áõ°¡´Â ERT¿¡ ´ëÇÑ ¼ö¿ä¸¦ Á÷Á¢ÀûÀ¸·Î Áõ°¡½ÃÄ×°í, Áø´Ü ¹æ¹ýÀÇ °³¼±À¸·Î ´õ ¸¹Àº ȯÀÚµéÀÌ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì°ú È¿¼Ò ºÐ¼®Àº ÆÄºê¸®º´ Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ERTÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ý°¨±â°¡ ¿¬ÀåµÇ°í È¿´ÉÀÌ °³¼±µÈ Â÷¼¼´ë ERT Á¦Á¦ÀÇ Áö¼ÓÀûÀÎ ¿¬±¸·Î ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 23¾ï ´Þ·¯
¿¹»ó ±Ý¾× 51¾ï ´Þ·¯
CAGR 8.2%

ÀÌ ½ÃÀåÀº ¶ÇÇÑ Á¤¸Æ Åõ¿©¿Í °æ±¸ Åõ¿© µî Åõ¿© °æ·Î¿¡ µû¶ó Ä¡·á¹ýÀ» ±¸ºÐÇϰí ÀÖ½À´Ï´Ù. Á¤¸Æ Ä¡·á´Â 2024³â 68.3%ÀÇ Á¡À¯À²À» Â÷ÁöÇϸç 2025-2034³â CAGR 8.1%·Î ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÆÄºê¸®º´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í À¯ÀüÀÚ ½ºÅ©¸®´× ÇÁ·Î±×·¥ÀÌ °³¼±µÇ¸é¼­ Áø´Ü °Ç¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¤¸ÆÁÖ»ç Ä¡·á ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. Àӻ󿬱¸¿¡¼­ ERTÀÇ Á¤¸Æ Åõ¿©°¡ Àå±âÀûÀ¸·Î Áõ»óÀ» ¾ÈÁ¤È­½ÃŰ´Â µ¥ È¿°úÀûÀ̶ó´Â »ç½ÇÀÌ ÀϰüµÇ°Ô ¹àÇôÁ® ¼±È£µÇ´Â Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ±×·¯³ª °æ±¸¿ë ¿ä¹ýÀº ÀáÀçÀûÀÎ ÆíÀǼº°ú ȯÀÚÀÇ ¼øÀÀµµ Çâ»óÀ¸·Î ÀÎÇØ ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â 2024³â 9¾ï 4,580¸¸ ´Þ·¯ÀÇ ÆÄºê¸®º´ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ 9¾ï 4,800¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ¿Ã¸®¸ç ½ÃÀå È®´ëÀÇ ÁÖ¿ä Áö¿ªÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ºÀåÀÇ ¿øµ¿·ÂÀº Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â, À¯º´·ü Áõ°¡, Èñ±ÍÁúȯ Ä¡·á¸¦ Àü¹®À¸·Î ÇÏ´Â ÁÖ¿ä ÇコÄÉ¾î ±â¾÷ÀÇ Á¸ÀçÀÔ´Ï´Ù. ¹Ì±¹ ³» Ä¡·á °Ç¼ö Áõ°¡´Â ³ôÀº ÀÇ·áºñ ¹× °­·ÂÇÑ »óȯ Á¤Ã¥°ú ÇÔ²² ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÆÄºê¸®º´ Ä¡·áÀÇ ¿¬±¸ °³¹ßÀÇ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, ¿©·¯ ÀÓ»ó½ÃÇè°ú ½Å¾à ½ÂÀÎÀ¸·Î °æÀï ±¸µµ¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ãß»ê ¹× ¿¹Ãø : Ä¡·áº°, 2021³â-2034³â

Á¦6Àå ½ÃÀå Ãß»ê ¹× ¿¹Ãø : Åõ¿© °æ·Îº°, 2021³â-2034³â

Á¦7Àå ½ÃÀå Ãß»ê ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021³â-2034³â

Á¦8Àå ½ÃÀå Ãß»ê ¹× ¿¹Ãø : Áö¿ªº°, 2021³â-2034³â

Á¦9Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Fabry Disease Treatment Market was valued at USD 2.3 billion in 2024 and is projected to grow at a CAGR of 8.2% during 2025-2034. The increasing demand for highly effective, targeted, and specific treatments for Fabry disease is driving market expansion worldwide. The condition, a rare genetic disorder caused by mutations in the GLA gene, leads to the buildup of harmful fatty substances in various organs, resulting in severe complications affecting the kidneys, heart, and nervous system. As awareness of Fabry disease continues to grow, healthcare providers and pharmaceutical companies are focusing on developing innovative therapies that address both the symptoms and underlying causes. With ongoing research and clinical advancements, new treatment options are emerging, giving patients improved outcomes and an enhanced quality of life. Increased funding from both public and private sectors, along with collaborations among biopharmaceutical companies, is expected to accelerate innovation in this market. Regulatory support, along with fast-track designations for novel therapies, is further expediting drug approvals, creating lucrative opportunities for industry participants. The competitive landscape is evolving, with companies investing heavily in research and development to bring more effective and accessible treatments to market.

Fabry Disease Treatment Market - IMG1

The market is categorized into several treatment options, with enzyme replacement therapy (ERT) leading the way. ERT was valued at USD 1.7 billion in 2024 and continues to dominate due to its established role as the standard treatment for Fabry disease. This therapy works by replacing the deficient enzyme alpha-galactosidase A, an essential component in managing the disease and preventing progressive organ damage. The rising prevalence of Fabry disease has directly increased the demand for ERT, with more patients gaining access to treatment due to improved diagnostic methods. Next-generation sequencing and enzyme assays have revolutionized Fabry disease diagnosis, enabling earlier and more accurate detection, which is further fueling the adoption of ERT. Ongoing research into next-generation ERT formulations with extended half-lives and improved efficacy is expected to sustain growth in this segment.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$2.3 Billion
Forecast Value$5.1 Billion
CAGR8.2%

The market also distinguishes treatments based on their route of administration, including intravenous and oral options. Intravenous treatments accounted for a 68.3% share in 2024 and are expected to continue growing at a CAGR of 8.1% during 2025-2034. The increasing awareness of Fabry disease and improvements in genetic screening programs have led to more diagnoses, which is driving demand for intravenous therapies. Clinical studies consistently show that intravenous ERT is more effective at stabilizing symptoms over the long term, making it the preferred treatment. However, oral therapies are gaining attention due to their potential convenience and improved patient adherence.

North America generated USD 945.8 million in revenue from the Fabry Disease Treatment Market in 2024, making it a key region for market expansion. Growth is driven by favorable government initiatives, rising incidence rates, and the presence of leading healthcare companies specializing in rare disease treatments. The increasing number of treatment procedures in the U.S., coupled with high healthcare expenditure and strong reimbursement policies, has significantly contributed to market growth. The region remains at the forefront of research and development in Fabry disease treatments, with multiple clinical trials and new drug approvals shaping the competitive landscape.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 – 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â